Understanding TK2d and the KYGEVVI Approval

Join us for an informative webinar exploring KYGEVVI™ (doxecitine and doxribtimine), the first FDA-approved treatment for thymidine kinase 2 deficiency (TK2d) in adults and pediatric patients with an age of symptom onset on or before 12 years. This session will cover: The basics of TK2d, including its genetic cause, symptoms, and how it is diagnosed The impact of TK2d on patients and families An…